Type 2 & other diabetes

Cardiorenal Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic‐Range Proteinuria: A Multi‐Institutional Target Trial Emulation

Diabetes Obes MetabPublished Retrospective cohort study

Main finding · MAKEResult — go to the resultHazard ratio 0.75 95% CI 0.65–0.86

Authors' conclusion

Among adults with T2DM and nephrotic-range proteinuria, SGLT2i versus DPP4i was associated with lower long-term risks of ESKD and all-cause mortality and no clear differences in cardiovascular or safety outcomes were observed.

Study context

Population
Adults with T2D and nephrotic-range proteinuria (UPCR > 3500 mg/g or UACR > 1967 mg/g), TriNetX network; mean UPCR 5181–5416 mg/gmatched cohort
Exposure
SGLT2i vs DPP-4i
Outcome
Major adverse kidney events (MAKE)
Methodological detailstarget trial emulation, new-user, active-comparator, propensity score matching (1:1), multi-institutional (TriNetX network)
  • Target trial emulation
  • New-user, active-comparator
  • Propensity score matching (1:1)
  • Multi-institutional (TriNetX network)

Main finding

MAKE

Hazard ratio

0.75

95% CI 0.65–0.86

By group

SGLT2ivs DPP4i
HR 0.75 (95% CI 0.65–0.86)

As reported in the abstract

Observational data: associations, not effects.

Secondary outcomes

OutcomeHR (95% CI)
ESKD on dialysisSGLT2ivs DPP4i0.73 (0.62–0.85)
All-cause mortalitySGLT2ivs DPP4i0.71 (0.55–0.91)

Cardiovascular events

No clear differences between groups in cardiovascular events

Safety

Safety outcomes (genital infection, ketoacidosis, hypoglycaemia, urinary tract infection)

No clear differences between groups in safety outcomes

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Cardiorenal Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic‐Range Proteinuria: A Multi‐Institutional Target Trial Emulation. Diabetes Obes Metab. Published 13 April 2026. doi:10.1111/dom.70764

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.